JAMAL MISLEH, MD
Hematology & Oncology Physician · NEWARK, DE
Individual Active NPI 1174665822
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 822 | 550,501 | $49,974,627 | $13,837,476 | $11,013,147 |
| 2023 | 833 | 590,958 | $48,644,652 | $13,111,207 | $10,424,676 |
| 2022 | 816 | 700,023 | $44,120,990 | $13,707,354 | $10,920,990 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 46,000 | $56 | $45 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 39,600 | $49 | $39 |
| J0896 | Injection, luspatercept-aamt, 0.25 mg | 39,448 | $40 | $32 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21,835 | $3 | $2 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 21,800 | $0 | $0 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17,820 | $45 | $36 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 14,916 | $26 | $20 |
| J0897 | Injection, denosumab, 1 mg | 12,840 | $26 | $20 |
| J1437 | Injection, ferric derisomaltose, 10 mg | 10,800 | $20 | $16 |
| J9312 | Injection, rituximab, 10 mg | 7,950 | $77 | $61 |
| J9041 | Injection, bortezomib, 0.1 mg | 6,850 | $2 | $1 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 6,455 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | C1-0008987 | DE |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Delaware
- NPI 1386720340
- NPI 1275976417
- NPI 1841269966
- NPI 1588614697
- NPI 1063743722
- NPI 1134486046
- NPI 1427008622
- NPI 1053625632
See all Hematology & Oncology Physician providers in Delaware →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.